F ibrin degradation products (FDPs) formation with subsequent release into bloodstream is a result of fibrinolytic system action. The main fibrinolytic enzyme plasmin is generated from inert precursor plasminogen by either tissuetype plasminogen activator (t-PA) or urokinase-type plasminogen activator [1] . According to molecular mechanism of fibrinolysis, plasminogen and its tissue-type activator from plasma bind to fibrin, and plasminogen activator converts proenzyme into plasmin. Fibrin formed during clotting process, as fibrinogen polyme rization result is a high-avid substrate and at the same time a stimulator for plasmin. Plasminogen/t-PA binding sites in D-regions subsequently Аα 148-160 and γ 312-324 are hidden in fibrinogen molecule and exposed under polymerization and fibrin clot formation [2] . The conversion provides increase of plasminogen and its activator local concentration, change of their conformation and orientation, resul ted in fast proenzyme activation and fibrin cleavage by newly formed plasmin.
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F ibrin degradation products (FDPs) formation with subsequent release into bloodstream is a result of fibrinolytic system action. The main fibrinolytic enzyme plasmin is generated from inert precursor plasminogen by either tissuetype plasminogen activator (t-PA) or urokinase-type plasminogen activator [1] . According to molecular mechanism of fibrinolysis, plasminogen and its tissue-type activator from plasma bind to fibrin, and plasminogen activator converts proenzyme into plasmin. Fibrin formed during clotting process, as fibrinogen polyme rization result is a high-avid substrate and at the same time a stimulator for plasmin. Plasminogen/t-PA binding sites in D-regions subsequently Аα 148-160 and γ 312-324 are hidden in fibrinogen molecule and exposed under polymerization and fibrin clot formation [2] . The conversion provides increase of plasminogen and its activator local concentration, change of their conformation and orientation, resul ted in fast proenzyme activation and fibrin cleavage by newly formed plasmin.
First step of degradation of individual fibrin(ogen) molecule by plasmin is αC-domains removal and X-fragment formation. Than plasmin cleaves one of the coiled-coil connector and removes onе of D-domains forming Y-fragment. The last stage is core fragments D and E formation. The lysis of polymeric fibrin cross-linked by FXIIIa leads to formation of intermediate high-molecular weight products that are the protofibril parts, for example DX n D, DXY, YY, DY. In vivo these molecules can form supramolecular complexes due to the noncovalent DDE-interaction [3] and contain different number of DDE-blocks. In this work the complex of soluble high molecular weight fibrin degradation products are called hmFDPs. During further degradation, these products are hydrolyzed to DDE-complexes (two covalently bound D-domains noncovalently associated with fragment E 1 or E 2 ) and then to core fragments DD and E 3 . Fibrin degradation products get in wide range of biological processes and affect all stages of hemostasis [4] . Soluble products of fibrin degradation stimulate t-PA-induced fibrinogen proteolysis in blood plasma [5] . FDPs activate inflammatory and/or structural cells and regulate smooth muscle cell migration [6] . Like fibrin, DDE-complex can bind plasminogen and its activator [7] . DD-fragment, a biomarker for hyperfibrinolytic disorders such as disseminated intravascular coagulation (DIC), attenuates the fibrin doi: http://dx.doi.org/10.15407/ubj88.02.016 polymerization, influences inflammatory process by interaction with monocytes and stimulate increased cytokine production in peripheral blood monocytes and leukemia cell lines [8] . Fibrin fragment E induces leukocyte cytokine expression and migration by binding vascular endothelial-cadherin and monocyte and neutrophil migration [9] . At the same time the effect of fibrin degradation products accumulated in clot surrounding during its lysis on fibrinolytic system activity is still unclear.
This study investigates the action of products of fibrin degradation by plasmin on the different stages of fibrinolytic process, such as plasminogen activation by t-PA and fibrin hydrolysis by plasmin.
Materials and Methods
Fibrinogen was purified from human plasma by fractionation with sodium sulfate [10] .
Plasminogen with an amino-terminal glutamic acid residue (Glu-plasminogen) was prepared from citrate donor plasma using the Lysine-sepharose 4B affinity chromatography [11] .
Plasmin was prepared by activation of Gluplasminogen with urokinase, immobilized to Sepharose 4B [11] .
Recombinant single-chain t-PA was a Boehringer Ingelheim product known as the trade name "Actylise".
desAB-fibrin was obtained by dissolving of thrombin fibrin clot formed in the presence of 50 mM ε-aminocaproic acid (ε-ACA) and parahydroxy mercury benzoate (0.35 mg/ml) in 20 mM acetic acid as described elsewhere [12] .
Cross-linked fibrin was obtained by thrombininduced fibrinogen polymerization (2 NIH of thrombin per 1 mg of fibrinogen) in the presence of calcium ions (0.25 M) at 25 °C during 4 h. Concentration of fibrinogen was 16 mg/ml.
Fibrin degradation products were prepared from plasmin digest of human cross-linked fibrin. Digestion was performed in 0.05 M TBS with 0.15 M NaCl (pH 7.4), concentration of plasmin was 0.2 CU/ ml. Endpoint degradation products E-and DD-fragments were obtained by 16-hour plasmic digestion at 25 °C as described elsewhere [13] . Reaction was inhibited by 1000 KIU aprotinin (Merckle GmbH) per 1 ml of reactive solution with ε-aminocaproic acid (ε-ACA) and EDTA in final concentrations 20 mM. Dialysis of digest was performed in 10 mM PBS pH 6.0 with 10 KIU/ml aprotinin, 20 mM ε-ACA and 20 mM EDTA at 4 °С. Fragments E and DD were purified by ion-exchange chromatography on CMSephadex G-50 (Fig. 1) . Fragment DD was eluted by 20 mM PBS with 300 mM NaCl (pH 7,6). Both fragments were then dialyzed in 0.05 M TBS with 0.15 M NaCl (pH 7.4) at 4 °С.
Early plasmic degradation products DDE-complex and high molecular weight fibrin fragments hmFDPs were isolated by modified method [14] using Sephacryl S300 (Fig. 2) . Cross-linked fibrin gel was hydrolysed by plasmin during 72 h at 25 °C by 0.01 CU plasmin per 1 ml of reaction mixture. Fibrin 2  12  22  32  42  52  62  72  82  92  102  112  122  132  142  152  162  172  182  192   E 3 DD 20 mM PBS with 300 mM NaCl (pH 7.6) concentration was 10 mg/ml. Hydrolysis products were purified in the presence of plasmin inhibitor aprotinin (25 KIU/ml) and then concentrated and dialyzed using 50K Amicon filtration system (Millipore). Fragments E 1 E 2 mixture was obtained by noncovalent complex DDE dissociation in presence of 3.0 M urea at 37 °C during 1 hour. Dissociation products were isolated by size-exclusion chromatography using Sephacryl S300 (Fig. 3) . Product of DDE dissociation fragment DD was not used in experiments because of its denaturation under dissociation conditions.
Protein concentrations were calculated by measurement of the absorbance at 280 and 320 nm using E 1% 280 and molecular weights, respectively: Glu-plasminogen, 17.0 and 92 000; plasmin, 17.0 and 84 000; tPA, 20.0 and 59 000; fibrinogen, 15.5 and 340 000; desAB fibrin, 14,48 and 300 000; hmFDPs, 16.0 and 500 000; fragment DDE-complex, 16.0 and 250 000; fragment DD, 20.0 and 180 000; fragments E 1 E 2 mixture, 10.0 and 53 000; fragment E 3 10.0 and 45 000 [14, 15] .
Effect of fibrin fragments on the t-PA-catalyzed conversion of plasminogen into plasmin was evaluated by determination of the amidolytic activity of the newly formed plasmin with chromogenic substrate
The assay system contained 0.22 µM Glu-plasminogen, 0.09 nM t-PA, 0.3 mM S 2251 , and 0.625 µM desAB-fibrin and/or 0.22 µM fibrin fragments in 0.05 M TBS with 0.15 M NaCl (pH 7.4) containing 0.05% Tween 80. The assay was performed in microtiter 96-well plate at 37 °C. The amidolytic activity was determined by measurement of the absorbance at 405 nm using Titertek Multiscan MC 96-well plate reader.
For the estimation of FDPs effect on fibrin clot lysis by t-PA-activated plasminogen, the turbidimetric method was applied as described in [14] . The final concentration of desAB-fibrin was 0.6 µM, Glu-plasminogen -0.02 µM, t-PA -0.001 µM. Fibrin fragments were added in 0.1-0.4 molar ratio to desAB-fibrin. The rate of fibrin clot lysis was calculated as V = 1/t 50% . Time of 50% lysis (t 50% ) was measured as the time period from the initiation step of the clot formation till the step characterized by 50% fall in absorbance from maximum.
To test plasmin inhibition by plasma inhibitors turbidimetric analysis of clot lysis was performed after subsequent preincubation of fibrin fragment with plasmin during 3 min and addition to the reaction mixture 1 -20 µl of plasminogen-depleted blood plasma as source of plasmin inhibitor α 2 -antiplasmin and desAB fibrin. The final concentration of desABfibrin was 0.6 µM, plasmin -0.02 µM. The max con- centration of α2-antiplasmin equal to 20 µl of blood plasma was 0.02-0.03 µM.
results and discussion
Potentiation of t-PA-mediated Glu-plasminogen activation by FDPs. All products of fibrin degradation by plasmin, apart from core fragment E 3 , have potentiating effect on plasminogen activation by t-PA (Fig. 4, A) . The rate of activation on intermediate fibrin degradation products hmFDPs and DDE-complex is similar to the rate on desAB fibrin, whereas endpoint degradation products decrease (DD) or completely lose (E 3 ) the potentiating ability. The mixture of DDE-complex components Fig. 4 fragments E 1 E 2 can interact with proenzyme and its activator and potentiate activation process, but after conversion to the fragment E 3 loses the stimulation ability (Fig. 4, B) . Summary potentiation of fragments DD and E 1 E 2 is close to the effect of initial fragment of DDE-complex. effect of FDPs on polymeric fibrin lysis by plasminogen. Turbidimetric analysis of desAB fibrin clot destruction by t-PA-activated plasminogen have shown a decrease of the reaction rate caused by intermediate degradation products hmFDPs and DDE (70 and 38% reduction of lysis rate, accordingly). At the same time, fragment DD does not attenuate the fibrin clot lysis by plasmin (Fig. 5) .
effect of FDPs on plasmin inactivation by α 2 -antiplasmin. None of fibrin fragments, except polymeric fragments hmFDPs, protects plasmin from α 2 -antiplasmin inhibition (Fig. 6) . Addition of blood plasma as α 2 -antiplasmin source into the reaction mixture of plasmin and fragment DD or DDE before desAB-fibrin addition leads to clot formation without next hydrolysis. Plasmin inhibition in the presence of fragments DD and DDE has the same pattern as control probe without any effectors. In the presence of hmFDPs, clot hydrolysis by plasmin is also observed, but the plasma amount which totally inhibits plasmin action in control probe results in only 50% inhibition.
To explain the differences in activity enhan cing of various FDPs, some features of structures of this fragments are considered in Fig. 7 . Soluble high-molecular weight FDPs contain fibrin protofibrils sections and composed of several E and D domains. Potentiation of t-PA-catalyzed plasminogen activation by this primarily degradation product is 86% of the level on desAB-fibrin. Such effect is caused by the fragment structure that is similar to fibrin. DDE-complex potentiation effect is close to the plasminogen activation on hmFDPs. We suppose that DDE conserves all plasminogen-and t-PAbinding sites which are exposed in hmFDPs.
It is well established that each D region contains t-PA-and plasminogen-binding sites that include sequences γ312-324 and Aα148-160, respectively [1, 17] . In polymeric fibrin these regions are exposed and they mediate ternary complex formation with proenzyme and its activator. D-domain containing fibrin fragments have different ability to interact with immobilized t-PA, anti-Aα148-160-mabs and anti-γ312-324-mabs: antibodies bound with DDE, but do not bind with fragment DD [18, 2] . On the other hand in some experiments [17, 19, 20] DD potentiated plasminogen activation process. Our results confirm potentiation ability of fibrin degradation product DD. Based on this data we assume that plasminogen-activation sites in D-domains remain exposed after destruction of DDE-interaction.
Less potentiation effect of fragment DD in contrast to DDE-complex is probably caused by the absence of E-fragment activation sites. Fragments E 1 
Fig. 5. effect of FDPs on fibrin clot lysis by tissue-type plasminogen activator-conversed Glu-plasminogen. The lysis rate changes were calculated by comparing the desAb-fibrin clot lysis in the presence of fibrin fragments with that without fragments. These values were than expressed as a percentage of clot lysis rate in the absence of fibrin fragments. The correlation coefficient r was calculated using linear regression analysis
The free form of fibrin central domain is the fragment E 3 , which lost amino acid sequences of all three peptide chains (Fig. 7) . α-Chains of fragment E are subjected to plasmin splitting off αGly17-Arg19 peptide. β-chains lose one of their N-terminal sequences of Gly-β15 to Lys-β53 during conversion to E 2 and the next one during free E 3 formation. Cterminal βLys122, γLys62 are also lost -E 3 contains C-terminal αLys78, βLeu120 and γLys58 [21] . The leakage of potentiation ability on plasminogen activation by t-PA after carboxypeptidase treatment of DDE-compex was found by Stewart and coworkers [22] . In our previous study we have shown that in fibrinogen early fragment E C-terminal lysine resi-dues of all 3 chain pairs and 16 or 23 amino acid residues of Aα-chain are essential for plasminogen conversion into plasmin. C-terminal lysines of fragment E Aα-and γ-chains and lysine-binding site of t-PA kringle 2 are responsible for the interaction between these proteins. Binding of fragment E to plasminogen is provided by N-terminal Aα1-19 and C-terminal Bβ120-122 regions. Late plasmic fibrinogen degradation product fragment EL loses the ability to potentiate plasmin generation but can bind proenzyme and its activator [23] . Thus, the loss of the potentiating action of fibrin fragment E 3 probably is associated with the removal of C-terminal lysines and N-terminal fragments from all three polypeptide chains. This data confirms that fragment E, as a component of DDE-comlex, is involved in plasminogen activation.
Intermediate fibrin degradation products like hmFDPs and DDE fragments can compete with fibrin clot for fibrinolytic system components and in this way attenuate the clot lysis that is confirmed by a decrease of polymeric fibrin lysis rate. Despite its ability to stimulate plasminogen activation by t-PA, DD fragment is not an effector for this process. Thus, endpoint fibrin degradation products in clot surroundings can bind plasminogen and t-PA, stimulate proenzyme activation, but do not affect clot destruction.
Ability to protect plasmin from inhibition by plasma α 2 -antiplasmin is inherent only in high molecular weight FDPs, but not in DDE-complex and fragment DD. We suppose it is a regulative mechanism of last fibrinolysis stages: when clot is dissolved to core fragments, plasmin bound to them is inhibited to protect other plasma proteins from nonspecific proteolysis.
Summarizing all the data, a presumable way of FDPs action on fibrinolytic process is in delay of clot lysis rate by the reversed feedback mechanism: more soluble fibrin fragments bind more plasminogen and t-PA and potentiate the activation, move them into bloodstream, where high molecular fibrin fragments are digested to endpoint products and plasmin bound to them are inhibited by the plasma inhibitors.
Fibrin degradation products accumulated in clots microsurrounding can bind plasminogen and its activator and stimulate plasmin formation outward the clot. The intermediate fibrin degradation fragments (hmFDPs) protect plasmin from α 2 -antiplasmin inhibition but under further fragmentation (DDE-complexes, then fragments DD and E 3 ) fibrin fragments loose this ability. Fibrinolytic system activity generated by them will be inhibited under the normal level of the plasmin inhibitor. Лізис фібринового згустку плазміноген/ плазміновою системою призводить до утво-рення низки продуктів деградації фібрину, які вивільнюються в кровотік. Фрагменти фібрину містять у своєму складі специфічні центри зв'язування компонентів фібринолітичної си-стеми і можуть взаємодіяти з ними. У роботі досліджено вплив продуктів деградації фібрину на різні етапи фібринолітичного процесу. Пока-зано, що розчинні високомолекулярні продукти деградації фібрину hmFDPs, фрагменти DDE-комплексу та DD, але не кінцевий продукт Е 3 , стимулюють реакцію активації плазміногену тканинним активатором. Одержана за дисоціації DDE-комплексу суміш фрагментів Е 1 Е 2 також виявляє стимулювальні властивості. Ранні про-дукти гідролізу полімерного фібрину hmFDPs та DDE-комплекс пригнічують швидкість лізису фібринового згустку плазміном, а високомолекулярні фрагменти hmFDPs захища-ють плазмін від інгібування α 2 -антиплазміном. Інгібітори плазми крові пригнічують активність плазміну, зв'язаного з DDE-комплексом і DD фрагментом. Одержані результати свідчать, що фібринові фрагменти, що утворюються під час тромболізису, можуть зв'язувати і виводити з об'єму згустку компоненти фібринолітичної си-стеми і в такий спосіб спричиняти його стійкість до гідролізу.
К л ю ч о в і с л о в а: продукти деградації фібрину, плазміноген, t-PA, активація, стимулю-вальний ефект, інгібування плазміну. Лизис фибринового сгустка плазминоген/ плазминовой системой приводит к образованию ряда продуктов деградации фибрина, которые освобождаются в кровоток. Фрагменты фибри-на содержат в своем составе специфические центры связывания компонентов фибриноли-тической системы и могут взаимодействовать с ними. В данной работе исследовано влияние продуктов деградации фибрина на различные этапы фибринолитического процесса. Показа-но, что растворимые высокомолекулярные про-дукты деградации фибрина hmFDPs, фрагменты DDE-комплекса и DD, но не конечный продукт Е 3 , стимулируют активацию плазминогена тка-невым активатором. Полученная при диссо-циации DDE-комплекса смесь фрагментов Е 1 Е 2 также проявляет стимулирующие свойства. Ранние продукты гидролиза полимерного фи-брина hmFDPs и DDE-комплекс снижают ско-рость лизиса фибринового сгустка плазмином, а высокомолекулярные фрагменты hmFDPs за-щищают плазмин от действия α 2 -антиплазмина. Ингибиторы плазмы крови подавляют актив-ность плазмина, связанного с DDE-комплексом и DD-фрагментом. Полученные результаты сви-детельствуют, что фрагменты фибрина, образо-ванные во время лизиса тромба, могут связы-вать и выводить из объема сгустка компоненты фибринолитической системы, приводя, таким образом, к его устойчивости к гидролизу. К л ю ч е в ы е с л о в а: продукты дегра-дации фибрина, плазминоген, t-PA, активация, стимулирующий эффект, ингибирование плаз-мина.
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